Abstract
AbstractThe clinical application of statins as anti‐hypercholesterolemia medications, while very beneficial, remains limited by intolerance and side effects. Statins increase the production of proprotein convertase subtilisin/kexin type 9 (PCSK9), which degrades low‐density lipoprotein (LDL) receptor and limits circulating LDL cholesterol (LDLC) uptake. PCSK9 also promotes cardiomyocyte and vascular smooth muscle cell apoptosis and vascular injury. Several PCSK9 inhibitors (evolocumab, alirocumab, and inclisiran) are highly effective at reducing plasma LDLC levels and moderately effective at protecting against cardiovascular disease. However, their long‐term use needs to take the following issues into account: i) PCSK9 deficiency leads to various pathologies like heart failure and liver steatosis, ii) PCSK9 regulates lipid homeostasis, iii) depletion of circulating PCSK9 may itself upregulate PCSK9 expression, and iv) the cost of available inhibitors is beyond the reach of most people. Therefore, the long‐term safety and affordability of PCSK9 inhibitors needs to be revisited and additional therapeutic options need to be explored.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
